Summit Therapeutics (LSE:SUMM) Beginning Cash Position : £56.21 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Beginning Cash Position?

Summit Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was £56.21 Mil.

Summit Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 (£34.03 Mil) to Dec. 2023 (£18.80 Mil) but then increased from Dec. 2023 (£18.80 Mil) to Mar. 2024 (£56.21 Mil).

Summit Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (£49.95 Mil) to Dec. 2022 (£58.94 Mil) and increased from Dec. 2022 (£58.94 Mil) to Dec. 2023 (£512.40 Mil).

Summit Therapeutics Beginning Cash Position Historical Data

The historical data trend for Summit Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Beginning Cash Position Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

22.08

47.50

49.95

58.94

512.40

Summit Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															534.45	56.21	34.03	18.80	56.21

Summit Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Summit Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (LSE:SUMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

SMMT:USA

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines